Literature DB >> 27748815

Differential expression of multidrug resistance‑related proteins in adriamycin‑resistant (pumc‑91/ADM) and parental (pumc‑91) human bladder cancer cell lines.

Man Zhao1, Shuliang Yu1, Man Zhang1.   

Abstract

Multidrug resistance (MDR) is the major obstacle to bladder cancer chemotherapy. Several mechanisms have been implicated in the development of MDR, including extrusion of the drug by cell membrane pumps, associated with P‑glycoprotein (P‑gp) and multidrug resistance‑associated protein (MRP); increased DNA damage repair, associated with topoisomerase II (Topo II); suppression of drug‑induced apoptosis, associated with p53; and regulation of cancer cell growth, associated with vascular endothelial growth factor (VEGF). In the present study, the expression levels of these five markers were detected in an adriamycin (ADM)‑resistant human bladder cancer cell line (pumc‑91/ADM) and its parental cell line (pumc‑91), in order to determine which marker is more important, or whether all of them participate in drug resistance. The expression levels of P‑gp, MRP, Topo II, VEGF and p53 were measured in the two cell lines by reverse transcription‑quantitative polymerase chain reaction, western blotting and immunohistochemistry. A significant increase in P‑gp, MRP and VEGF, and a decrease in Topo II mRNA expression were detected in the pumc‑91/ADM drug‑resistant cell line compared with the pumc‑91 cell line; however, no difference in p53 mRNA expression was detected between the cells. In pumc‑91/ADM cells, the protein expression levels of P‑gp and MRP were upregulated, whereas Topo II was significantly decreased. However, no marked differences in p53 or VEGF expression were detected between the two cell lines at the protein level. The cytoplasmic and cell membrane localization of P‑gp and MRP, the cytoplasmic localization of VEGF, and the nuclear localization of p53 and Topo II were confirmed in the two cell lines. The present study detected increased P‑gp and MRP, and reduced Topo II expression in pumc‑91/ADM cells compared with pumc‑91 cells; however, no difference was detected in p53 and VEGF expression between the cell lines. In conclusion, a significant upregulation of MRP and downregulation of Topo II were detected in the ADM‑resistant human bladder cancer cell line (pumc‑91/ADM) compared with in the parental cell line (pumc‑91).

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27748815     DOI: 10.3892/mmr.2016.5806

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  4 in total

1.  Vasohibin 1 inhibits Adriamycin resistance in osteosarcoma cells via the protein kinase B signaling pathway.

Authors:  Wei Huang; Yangguang Ren; Hui Liu
Journal:  Oncol Lett       Date:  2018-02-16       Impact factor: 2.967

2.  A new niclosamide derivatives-B17 can inhibit urological cancers growth through apoptosis-related pathway.

Authors:  Chia-Lun Wu; Chun-Liang Chen; Hsu-Shan Huang; Dah-Shyong Yu
Journal:  Cancer Med       Date:  2018-06-28       Impact factor: 4.452

3.  Small Nucleolar RNAs Determine Resistance to Doxorubicin in Human Osteosarcoma.

Authors:  Martina Godel; Deborah Morena; Preeta Ananthanarayanan; Ilaria Buondonno; Giulio Ferrero; Claudia M Hattinger; Federica Di Nicolantonio; Massimo Serra; Riccardo Taulli; Francesca Cordero; Chiara Riganti; Joanna Kopecka
Journal:  Int J Mol Sci       Date:  2020-06-24       Impact factor: 5.923

4.  Resveratrol effects in bladder cancer: A mini review.

Authors:  Tamires Cunha Almeida; Glenda Nicioli da Silva
Journal:  Genet Mol Biol       Date:  2021-03-22       Impact factor: 1.771

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.